Kura Oncology is dedicated to helping patients with cancer achieve long-lasting remission through targeted and well-tolerated treatments. Their mission is to realize the promise of precision medicines to improve the lives of cancer patients. With a deep understanding of cancer biology, Kura Oncology develops medicines that treat cancer with precision and minimal damage to healthy cells.

Their pipeline of novel precision medicines focuses on expanding patient populations and leveraging smart treatment combinations to overcome resistance and redefine patient outcomes. They are committed to addressing the long-standing challenges in cancer treatment by advancing drug candidates and targeting previously untapped molecular drivers of the disease. At Kura Oncology, they offer a range of products and services including Ziftomenib, Tipifarnib, and KO-2806, which are part of their innovative pipeline of precision medicines.

They also provide access to investigational drugs outside of clinical studies for eligible patients. With a team of experts led by President and CEO Troy Wilson, Ph. D., J.

D., Kura Oncology is at the forefront of developing targeted therapies and driving advancements in cancer care. Their commitment to precision medicines and patient-centered care sets them apart in the field of oncology